Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.

Autor:	Li QK; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA.; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions Baltimore, MD 21287, USA., Lih TM; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA., Wang Y; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA., Hu Y; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA., Höti N; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA., Chan DW; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA.; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions Baltimore, MD 21287, USA.; Department of Urology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions Baltimore, MD 21287, USA., Zhang H; Department of Pathology, Johns Hopkins University Baltimore, MD 21287, USA.; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions Baltimore, MD 21287, USA.; Department of Urology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions Baltimore, MD 21287, USA.
Jazyk:	angličtina
Zdroj:	American journal of cancer research [Am J Cancer Res] 2022 Mar 15; Vol. 12 (3), pp. 1323-1336. Date of Electronic Publication: 2022 Mar 15 (Print Publication: 2022).
Abstrakt:	Prostate cancer (PCa) is a heterogeneous group of tumors, including non-aggressive (NAG) and aggressive (AG) cancer, with variable clinical outcomes. Clinically, in order to assess the aggressiveness of a PCa, a core needle biopsy of a tumor is usually obtained to evaluate the Gleason pattern and score of the tumor. However, it may be difficult to assign on a small biopsy sample using histology. Therefore, additional tool is needed to aid in the assessment. We studied the diagnostic utility of 12 protein markers to identify AG tumors using immunohistochemistry (IHC) and tumor tissue microarray (TMA), including 215 cores of PCa and 111 cores of tumor-matched normal adjacent tissue (NAT). Protein markers were evaluated for their potential utility as single or combined panels for identification of AG. Of 12 proteins, PSMA, phospho-EGFR, AR and P16 were over-expressed in AG. Galectin-3, DPP4 and MAN1B1 revealed stronger staining patterns in NAG. The sensitivity and specificity of individual marker varied widely. Based on AUC values of individual marker, we constructed two- and three-marker panels. In two-marker panels, especially in the panel of DPP4 and PSMA, the AUC value reached 0.83 (ranging from 0.76 to 0.83). In three-marker panels, containing both DPP4 and PSMA with either Galectin-3 or phospho-EGFR, the AUC value reached 0.86 (ranging from 0.83 to 0.86). The specificities at 95% sensitivity of three-marker panels were also significantly improved. In addition to Gleason score, our IHC panels provide a practical tool to assess the aggressiveness of PCa. Competing Interests: None. (AJCR Copyright © 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu